Dr Ashraf Elghandour, PhD - Alexandria University - professor

Dr Ashraf Elghandour


Alexandria University


alexandria | Egypt

Main Specialties: Hematology, Hematology & Oncology, Infectious Disease, Internal Medicine

Additional Specialties: Hematology

ORCID logohttps://orcid.org/0000-0002-8841-048X

Top Author

Dr Ashraf Elghandour, PhD - Alexandria University - professor

Dr Ashraf Elghandour



Professor Dr Ashraf El Ghandour graduated from the Faculty Of Medicine, Alexandria University. He then got his Clinical MD in Haematology in 1997. He held many positions through out his career. Professor Dr Ashraf is currently the Vice Dean for Postgraduate Studies and Researches and assigned as acting Dean from 1st of August 2016 till end of October 2016. Previously he was the Head Of the Haematology Unit, Alexandria University from the period of August 2013 till December 2014 and General Director of Internal Medicine Department from 2009 till 2010. He is also the founder of Bone Marrow Transplantation and Stem Cell Lab Unit in Al Moasaat Alexandria University Hospital, Member of Infection Control Committee in Alexandria Faculty Of Medicine as well as Director of Training Teaching Program for House Officers and Internal Medicine Residents. He is also involved in many Multi-Centre International trials such as PI, and has many publications in peer reviewed journals such as Lancet and blood especially in the field of Multiple Myeloma and Malignant Haematology.

Primary Affiliation: Alexandria University - alexandria , Egypt


Additional Specialties:

Research Interests:

View Dr Ashraf Elghandour’s Resume / CV


Jan 1987
Alexandria University Faculty of Medicine


Jan 2014
Alexandria University Faculty of Medicine
vice dean for postgraduate




59Profile Views

31PubMed Central Citations

A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.

The New England journal of medicine

BACKGROUND:Deoxygenated sickle hemoglobin (HbS) polymerization drives the pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has potential to favorably modify disease outcomes. Voxelotor is an HbS polymerization inhibitor. METHODS:In a multicenter, phase 3, double-blind, randomized, placebo-controlled trial, we compared the efficacy and safety of two dose levels of voxelotor (1500 mg and 900 mg, administered orally once daily) with placebo in persons with sickle cell disease. The primary end point was the percentage of participants who had a hemoglobin response, which was defined as an increase of more than 1.0 g per deciliter from baseline at week 24 in the intention-to-treat analysis. RESULTS:A total of 274 participants were randomly assigned in a 1:1:1 ratio to receive a once-daily oral dose of 1500 mg of voxelotor, 900 mg of voxelotor, or placebo. Most participants had sickle cell anemia (homozygous hemoglobin S or hemoglobin Sβ0-thalassemia), and approximately two thirds were receiving hydroxyurea at baseline. In the intention-to-treat analysis, a significantly higher percentage of participants had a hemoglobin response in the 1500-mg voxelotor group (51%; 95% confidence interval [CI], 41 to 61) than in the placebo group (7%; 95% CI, 1 to 12). Anemia worsened between baseline and week 24 in fewer participants in each voxelotor dose group than in those receiving placebo. At week 24, the 1500-mg voxelotor group had significantly greater reductions from baseline in the indirect bilirubin level and percentage of reticulocytes than the placebo group. The percentage of participants with an adverse event that occurred or worsened during the treatment period was similar across the trial groups. Adverse events of at least grade 3 occurred in 26% of the participants in the 1500-mg voxelotor group, 23% in the 900-mg voxelotor group, and 26% in the placebo group. Most adverse events were not related to the trial drug or placebo, as determined by the investigators. CONCLUSIONS:In this phase 3 randomized, placebo-controlled trial involving participants with sickle cell disease, voxelotor significantly increased hemoglobin levels and reduced markers of hemolysis. These findings are consistent with inhibition of HbS polymerization and indicate a disease-modifying potential. (Funded by Global Blood Therapeutics; HOPE ClinicalTrials.gov number, NCT03036813.).


View Article
June 2019
2 Reads

The study of different chromosomal aberrations, CD38 and ZAP-70 in chronic lymphocytic leukemia patients.

Egypt J Immunol 2011 ;18(2):77-93

Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Egypt.

View Article

Download full-text PDF

November 2012
16 Reads

The study of different chromosomal aberrations, CD38 and ZAP-70 in chronic lymphocytic leukemia patients.

The Egyptian journal of immunology/Egyptian Association of Immunologists

View Article
2 Reads

6036 POSTER Low dose thalidomide as maintenance in multiple myeloma

European Journal of Cancer Supplements

View Article
October 2007
3 Reads